. Now a recent study from the Levine laboratory has While we are all acutely aware of the alarmingly high demonstrated an extremely important mechanism of incidence of cancer in people, these numbers obscure regulating Mdm2 expression that contributes to not only the fact that at a cellular level, full malignant transformathe development of cancer through the acquisition of tion is an extremely rare occurrence. We are, in fact, somatic alterations, but also to our overall susceptibility efficiently protected from tumorigenesis by a complex to cancer (Bond et al.
approximately six hot spots for mutation that together comprise nearly 40% of all these mutations. Such mutamembers possess a germline mutant form of p53 ,and generation of such mice could genotypically and phenotions either affect direct DNA contacts of the core or have a more general effect on the conformation of this typically mimic such patients' disease characteristics. Indeed, when Olive et al., compared their mt/ϩ mice to domain. Why such strong selection for the expression of mutant p53 exists in cancers has been the topic of p53 ϩ/Ϫ mice significant differences in tumor spectra were observed. R270H/ϩ mice had numerous carcinomuch speculation. Is the acquisition of a mutant p53 (as seen in human cancer) equivalent to the loss of p53 mas (a form of cancer that is very rare in ϩ/Ϫ mice) that were more invasive and metastatic, as well as an altogether (as in the knockout mice)? In other words, are the missense mutant forms of p53 essentially neutral increased frequency of B cell lymphomas. On the other hand, R172H/ϩ mice had increased frequency of metaversions that lack both tumor-suppressing and -promoting function, or do they contribute to the process of static osteosarcomas. In their study about half of the tumors had lost the wild-type allele. These data suggest cancer progression? There are numerous lines of evidence derived from basic and clinical studies that have that while the dominant negative effect of mutants is possible, there is likely to be some additional compofavored the latter possibility although until recently none have provided either definitive physiological evidence nent(s) provided by mutant p53 in this model. This is consistent with a result from Lang et al. based on the for this or extensive mechanistic insight. One possible explanation is that these mutant p53 proteins oligofact that loss of p53 rescues the early embryonic lethal phenotype of knocking out Mdm2. If mutant p53 serves merize with wild-type p53 through the C-terminal tetramerization domain and so inactivate any wild-type p53 to fully and solely block wild-type p53 function, then mt/ϩ mice should also rescue the Mdm2 Ϫ/Ϫ lethality, a coexpressed in the cells though a dominant-negative mechanism. This may certainly contribute to the preferresult that was not observed. To determine whether the mutant p53 present in a ential selection of this type of mutations, but is unlikely to be the whole story. For one thing, advanced tumors cell that lacks wild-type p53 has any function, the Jacks group generated mice expressing only each of the murarely possess both wild-type and mutant forms of p53; loss of heterozygosity at the p53 locus is a very frequent tant p53 hot spot alleles described above. Indeed, they found mutant p53-bearing mice displayed a marked difevent, with tumors retaining only the mutant form of the protein.
ference in tumor spectra, with carcinomas, hemangisarcomas, and T cell lymphomas occurring with signifiIn fact, there is a rather extensive literature documenting both dominant-negative effects of mutant forms of cantly higher frequencies than seen in Ϫ/Ϫ mice. When amination of mutant p53 in the engineered mice produced by both groups showed that high levels of mutant p53 were found in the majority (but not all) of the tumors that were examined. In contrast, normal cells from these mice did not express high levels of mutant p53. This suggests that the environment of a tumor cell has one or more secondary events that are required to stabilize p53 other than the simple lack of induced Mdm2. Further experiments performed by both groups using cells cultured from the mice showed that the presence of mutant p53 has a promoting effect on cell growth and division in the absence of any wild-type p53. Thus, the two groups have come to essentially the same conclusion (although with some differences in their data sets) that the presence of a mutant p53 influences the process of tumorigenesis in a manner that can be distinct from simply deleting wild-type p53. How might such an oncogenic gain of function be brought showed that when p53 siRNA was introduced the C57BL/6 background. Regardless of these differinto a tumor cell line derived from their mt/ϩ mice (that ences, the above data together support the likelihood had lost the wild-type p53 allele), ectopically expressed that, in their natural context, mutant p53 proteins can p63 and p73 transactivation of a p21 promoter reporter affect tumor spectra and properties. Note, however, that construct was increased. Moreover, the same siRNA led while there were either different or more metastatic tuto increased expression of endogenous p21 in mouse mors, mutant p53-expressing mice did not die more cells that was presumably the result of increased activity quickly than p53 null mice, with both sets averaging about by endogenous p63/p73. Reciprocally, they also found 4.5 months.
that siRNA knock-down of p63 and p73 had selective Additional interesting observations were made. For impact on cells depending upon whether they express example, it is well described that tumor-derived mismutant p53: Ras-induced foci were increased in mt/mt sense mutant forms of p53 are frequently expressed at cells compared with Ϫ/Ϫ cells, and siRNA reduction of much higher levels than is wild-type p53 in human tup63/p73 increased foci in the Ϫ/Ϫ cells but not in the mors. In fact, simply being able to detect p53 by immumt/mt cells, suggesting that the p53 homologs were nostaining is often taken by pathologists as evidence already compromised in the mutant p53 expressing that a tumor expresses mutant p53. The most likely cells. explanation for this is that transcriptionally inert mutant All told, it is clear that the p53 pathway can be disforms of p53 cannot induce the synthesis of Mdm2 that rupted through many mechanisms. Although there may be some redundancy between these, different points of normally keeps wild-type p53 levels extremely low. Ex-perturbation can result in substantially different results plore. A compound (Nutlin) that disrupts the interaction (see Figure 1) Levine, Lozano, and Jacks laboratories underscore the cells to either the SNP309 or other SNPs? It is interesting importance of knowing not only whether, but also how, to consider the possibility that variations in SNPs might p53 has been disturbed in a cancer. These studies will explain the differences in tumor development in different certainly provide impetus for further basic and translamouse strains expressing mutant p53. The extremely tional approaches to the ever-increasing complexity of high frequency of the SNP309 polymorphism, at least the field of p53. in the populations examined by the Levine group, is also
